Boston Scientific Corp. is bulking up its urology portfolio with the addition of NxThera Inc., a developer of the Rezῡm water vapor therapy system for benign prostatic hyperplasia (BPH), or enlarged prostate. Boston Scientific already holds a minority investment in the privately held Minnesota company, and has agreed to buy the firm outright for $306m upfront. The deal also includes additional commercial milestone payments of up to $100m over the next four years.
Boston Scientific had made its first investment in NxThera in December 2015, leading a $40m round, and the two companies forged another connection when Boston Scientific acquired American Medical Systems'...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?